Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEXO.L Regulatory News (EXO)

  • There is currently no data for EXO

Director/PDMR Shareholding

29 Nov 2016 09:00

RNS Number : 3911Q
Exova Group PLC
29 November 2016
Β 

EXOVA GROUP PLC

Notification of transactions of Directors and PDMRs

Β 

On 28 November 2016, Paul Barry, a person discharging managerial responsibilities ("PDMR"), sold 29,389 ordinary shares of 1 pence each ("Shares") in Exova Group plc (the "Company") as set out in column 3 in order to discharge tax liabilities arising upon exercise of a bonus share award as set out in the Company's RNS announcement dated 24 November 2016.

1. Name

2. Status

3. Number of Shares sold and price per Share

Paul Barry

PDMR

29,389 at Β£1.84 per Share

Following the sale, Paul Barry's total shareholding in the capital of Exova Group plc is 60,511 ordinary shares, representing 0.02 per cent. of the voting share capital of Exova Group plc.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Paul Barry

2

Reason for the notification

a)

Position/status

PDMR - Group Managing Director, Industries

b)

Initial notification / Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Exova Group plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Ordinary shares of 1p each

Β 

Β 

Β 

GB00BKY7HG11

b)

Nature of the transaction

Sale of shares in order to discharge tax liabilities arising upon exercise of a bonus share award as set out in the Company's RNS announcement dated 24 November 2016.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.84

29,389

d)

Aggregated information

- Aggregated volume

- Price

Β 

Β 

N/A

e)

Date of the transaction

28 November 2016

f)

Place of the transaction

London

Β 

This notification is made in accordance with Article 19 of the Market Abuse Regulation and the Disclosure and Transparency Rules.

For and on behalf of Exova Group plc

Date: 29 November 2016

Neil MacLennan

General Counsel & Company SecretaryTelephone: 0131 333 8053

Β 

About Exova

Exova is one of the world's leading laboratory-based testing groups, trusted by organisations to test and advise on the safety, quality and performance of their products and operations. Headquartered in Edinburgh, UK, Exova operates 138 laboratories and offices in 33 countries and employs more than 4,300 people throughout Europe, the Americas, the Middle East, Asia/Asia Pacific and Africa.

Exova's capabilities help to extend asset life, bring predictability to applications, and shorten the time to market for customers' products, processes and materials. With over 90 years' experience, Exova specialises in testing across a number of key sectors ranging from Aerospace to Fire & Building Products; Oil & Gas and Industrials; Infrastructure & Environment; Automotive; and Health Sciences.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHUKONRNNAAURA
Date   Source Headline
28th Mar 201711:45 amRNSForm 8.5 (EPT/RI) Exova Group Plc
28th Mar 201711:16 amRNSForm 8.5 (EPT/RI)
28th Mar 201711:00 amRNSForm 8.5 (EPT/RI)
28th Mar 201710:33 amRNSForm 8.3 - Exova Group plc
28th Mar 20177:00 amBUSForm 8.3 - Exova Group Plc
27th Mar 20173:12 pmBUSForm 8.3 - Exova Group Plc
27th Mar 20173:05 pmRNSForm 8.3 - Exova Group Plc
27th Mar 201710:37 amRNSForm 8.3 - Exova Group PLC
27th Mar 20179:15 amRNSRule 2.9 Announcement
27th Mar 20177:00 amRNSPossible Offer for Exova Group plc
28th Feb 20177:00 amRNSFinal Results
12th Jan 20177:00 amRNSPost-close Trading Update
21st Dec 201612:06 pmRNSChanges to Nomination Committee
6th Dec 20167:02 amRNSDevelopment of global laboratory portfolio
1st Dec 20163:15 pmRNSVoting Rights and Capital
29th Nov 20169:00 amRNSDirector/PDMR Shareholding
24th Nov 20169:00 amRNSIssue of Equity
24th Nov 20169:00 amRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSDivisional Reporting of Historic Results
24th Nov 20167:00 amRNSTrading Statement
27th Oct 20164:35 pmRNSPrice Monitoring Extension
24th Oct 20168:51 amRNSTR-1: Notification of Major Interest in Shares
21st Oct 20169:27 amRNSTR-1: Notification of Major Interest in Shares
4th Oct 20164:35 pmRNSPrice Monitoring Extension
21st Sep 20167:00 amRNS2016 Capital Markets Day
13th Sep 20169:00 amRNSTR-1: Notification of Major Interest in Shares
31st Aug 20167:00 amRNSHalf-year Report
21st Jul 20164:40 pmRNSSecond Price Monitoring Extn
21st Jul 20164:35 pmRNSPrice Monitoring Extension
4th Jul 20167:00 amRNSExova acquires Jones Environmental Forensics
1st Jul 20167:00 amRNSExova completes sale of Food, Water & Pharma Biz
29th Jun 20163:07 pmRNSNotice of Results and Capital Markets Day
28th Jun 20164:40 pmRNSSecond Price Monitoring Extn
28th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Jun 20168:00 amRNSDirector Declaration
19th May 20161:46 pmRNSResult of AGM
19th May 20161:39 pmRNSAGM Statement
19th May 20167:00 amRNSExova sells UK & Ire Food, Water & Pharma Business
19th May 20167:00 amRNSTrading Update
10th May 20169:00 amRNSDirector/PDMR Shareholding
5th May 201610:00 amRNSIssue of Equity
5th May 201610:00 amRNSDirector/PDMR Shareholding
22nd Apr 20162:00 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
19th Apr 20162:00 pmRNSDirector/PDMR Shareholding
11th Apr 20169:43 amRNSAnnual Report & Accounts 2015 & Notice of 2016 AGM
1st Apr 20169:00 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
9th Mar 20169:00 amRNSDirector/PDMR Shareholding
7th Mar 20169:00 amRNSDirector/PDMR Shareholding
3rd Mar 20167:00 amRNSFinal Results
18th Feb 201610:16 amRNSDisclosure of Home Member State

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.